Research ArticleArticle
Whole-body Magnetic Resonance Imaging Inflammation in Peripheral Joints and Entheses in Axial Spondyloarthritis: Distribution and Changes during Adalimumab Treatment
Simon Krabbe, Iris Eshed, Inge Juul Sørensen, Bente Jensen, Jakob M. Møller, Lone Balding, Ole Rintek Madsen, Susanne Juhl Pedersen and Mikkel Østergaard
The Journal of Rheumatology April 2019, jrheum.181159; DOI: https://doi.org/10.3899/jrheum.181159
Simon Krabbe
From the Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen; Center for Rheumatology and Spine Diseases, Frederiksberg Hospital, Frederiksberg; Department of Radiology, Herlev and Gentofte Hospital, Herlev; Center for Rheumatology and Spine Diseases, and Gentofte Hospital, Hellerup, Denmark; Department of Diagnostic Imaging, Sheba Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. The investigator-initiated study was supported by AbbVie, which manufactures adalimumab. S.K. received grants from The Danish Rheumatism Association and Rigshospitalet. S.J.P. has received speaker fees from MSD, Pfizer, AbbVie, Novartis, and UCB; has been an advisory board member for AbbVie, and received research support from AbbVie and MSD. M.Ø. has received research support and/or consultancy/speaker fees from AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Centocor, GSK, Hospira, Janssen, Merck, Mundipharma, Novartis, Novo, Orion, Pfizer, Regeneron, Schering-Plough, Roche, Takeda, UCB, and Wyeth. S. Krabbe, MD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; I. Eshed, MD, Department of Diagnostic Imaging, Sheba Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University; I. Juul Sørensen, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; B. Jensen, MD, Center for Rheumatology and Spine Diseases, Frederiksberg Hospital; J.M. Møller, MSc, Department of Radiology, Gentofte Hospital; L. Balding, MD, Department of Radiology, Gentofte Hospital; O.R. Madsen, MD, PhD, Center for Rheumatology and Spine Diseases, Herlev and Gentofte Hospital; S.J. Pedersen, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; M. Østergaard, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen. Dr. Pedersen and Dr. Østergaard are co-senior authors. Address correspondence to Dr. S. Krabbe, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Valdemar Hansens Vej 17, DK-2600 Glostrup, Denmark. E-mail: simonkrabbe@gmail.com. Accepted for publication March 1, 2019.
Iris Eshed
From the Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen; Center for Rheumatology and Spine Diseases, Frederiksberg Hospital, Frederiksberg; Department of Radiology, Herlev and Gentofte Hospital, Herlev; Center for Rheumatology and Spine Diseases, and Gentofte Hospital, Hellerup, Denmark; Department of Diagnostic Imaging, Sheba Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. The investigator-initiated study was supported by AbbVie, which manufactures adalimumab. S.K. received grants from The Danish Rheumatism Association and Rigshospitalet. S.J.P. has received speaker fees from MSD, Pfizer, AbbVie, Novartis, and UCB; has been an advisory board member for AbbVie, and received research support from AbbVie and MSD. M.Ø. has received research support and/or consultancy/speaker fees from AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Centocor, GSK, Hospira, Janssen, Merck, Mundipharma, Novartis, Novo, Orion, Pfizer, Regeneron, Schering-Plough, Roche, Takeda, UCB, and Wyeth. S. Krabbe, MD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; I. Eshed, MD, Department of Diagnostic Imaging, Sheba Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University; I. Juul Sørensen, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; B. Jensen, MD, Center for Rheumatology and Spine Diseases, Frederiksberg Hospital; J.M. Møller, MSc, Department of Radiology, Gentofte Hospital; L. Balding, MD, Department of Radiology, Gentofte Hospital; O.R. Madsen, MD, PhD, Center for Rheumatology and Spine Diseases, Herlev and Gentofte Hospital; S.J. Pedersen, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; M. Østergaard, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen. Dr. Pedersen and Dr. Østergaard are co-senior authors. Address correspondence to Dr. S. Krabbe, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Valdemar Hansens Vej 17, DK-2600 Glostrup, Denmark. E-mail: simonkrabbe@gmail.com. Accepted for publication March 1, 2019.
Inge Juul Sørensen
From the Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen; Center for Rheumatology and Spine Diseases, Frederiksberg Hospital, Frederiksberg; Department of Radiology, Herlev and Gentofte Hospital, Herlev; Center for Rheumatology and Spine Diseases, and Gentofte Hospital, Hellerup, Denmark; Department of Diagnostic Imaging, Sheba Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. The investigator-initiated study was supported by AbbVie, which manufactures adalimumab. S.K. received grants from The Danish Rheumatism Association and Rigshospitalet. S.J.P. has received speaker fees from MSD, Pfizer, AbbVie, Novartis, and UCB; has been an advisory board member for AbbVie, and received research support from AbbVie and MSD. M.Ø. has received research support and/or consultancy/speaker fees from AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Centocor, GSK, Hospira, Janssen, Merck, Mundipharma, Novartis, Novo, Orion, Pfizer, Regeneron, Schering-Plough, Roche, Takeda, UCB, and Wyeth. S. Krabbe, MD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; I. Eshed, MD, Department of Diagnostic Imaging, Sheba Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University; I. Juul Sørensen, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; B. Jensen, MD, Center for Rheumatology and Spine Diseases, Frederiksberg Hospital; J.M. Møller, MSc, Department of Radiology, Gentofte Hospital; L. Balding, MD, Department of Radiology, Gentofte Hospital; O.R. Madsen, MD, PhD, Center for Rheumatology and Spine Diseases, Herlev and Gentofte Hospital; S.J. Pedersen, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; M. Østergaard, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen. Dr. Pedersen and Dr. Østergaard are co-senior authors. Address correspondence to Dr. S. Krabbe, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Valdemar Hansens Vej 17, DK-2600 Glostrup, Denmark. E-mail: simonkrabbe@gmail.com. Accepted for publication March 1, 2019.
Bente Jensen
From the Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen; Center for Rheumatology and Spine Diseases, Frederiksberg Hospital, Frederiksberg; Department of Radiology, Herlev and Gentofte Hospital, Herlev; Center for Rheumatology and Spine Diseases, and Gentofte Hospital, Hellerup, Denmark; Department of Diagnostic Imaging, Sheba Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. The investigator-initiated study was supported by AbbVie, which manufactures adalimumab. S.K. received grants from The Danish Rheumatism Association and Rigshospitalet. S.J.P. has received speaker fees from MSD, Pfizer, AbbVie, Novartis, and UCB; has been an advisory board member for AbbVie, and received research support from AbbVie and MSD. M.Ø. has received research support and/or consultancy/speaker fees from AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Centocor, GSK, Hospira, Janssen, Merck, Mundipharma, Novartis, Novo, Orion, Pfizer, Regeneron, Schering-Plough, Roche, Takeda, UCB, and Wyeth. S. Krabbe, MD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; I. Eshed, MD, Department of Diagnostic Imaging, Sheba Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University; I. Juul Sørensen, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; B. Jensen, MD, Center for Rheumatology and Spine Diseases, Frederiksberg Hospital; J.M. Møller, MSc, Department of Radiology, Gentofte Hospital; L. Balding, MD, Department of Radiology, Gentofte Hospital; O.R. Madsen, MD, PhD, Center for Rheumatology and Spine Diseases, Herlev and Gentofte Hospital; S.J. Pedersen, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; M. Østergaard, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen. Dr. Pedersen and Dr. Østergaard are co-senior authors. Address correspondence to Dr. S. Krabbe, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Valdemar Hansens Vej 17, DK-2600 Glostrup, Denmark. E-mail: simonkrabbe@gmail.com. Accepted for publication March 1, 2019.
Jakob M. Møller
From the Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen; Center for Rheumatology and Spine Diseases, Frederiksberg Hospital, Frederiksberg; Department of Radiology, Herlev and Gentofte Hospital, Herlev; Center for Rheumatology and Spine Diseases, and Gentofte Hospital, Hellerup, Denmark; Department of Diagnostic Imaging, Sheba Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. The investigator-initiated study was supported by AbbVie, which manufactures adalimumab. S.K. received grants from The Danish Rheumatism Association and Rigshospitalet. S.J.P. has received speaker fees from MSD, Pfizer, AbbVie, Novartis, and UCB; has been an advisory board member for AbbVie, and received research support from AbbVie and MSD. M.Ø. has received research support and/or consultancy/speaker fees from AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Centocor, GSK, Hospira, Janssen, Merck, Mundipharma, Novartis, Novo, Orion, Pfizer, Regeneron, Schering-Plough, Roche, Takeda, UCB, and Wyeth. S. Krabbe, MD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; I. Eshed, MD, Department of Diagnostic Imaging, Sheba Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University; I. Juul Sørensen, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; B. Jensen, MD, Center for Rheumatology and Spine Diseases, Frederiksberg Hospital; J.M. Møller, MSc, Department of Radiology, Gentofte Hospital; L. Balding, MD, Department of Radiology, Gentofte Hospital; O.R. Madsen, MD, PhD, Center for Rheumatology and Spine Diseases, Herlev and Gentofte Hospital; S.J. Pedersen, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; M. Østergaard, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen. Dr. Pedersen and Dr. Østergaard are co-senior authors. Address correspondence to Dr. S. Krabbe, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Valdemar Hansens Vej 17, DK-2600 Glostrup, Denmark. E-mail: simonkrabbe@gmail.com. Accepted for publication March 1, 2019.
Lone Balding
From the Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen; Center for Rheumatology and Spine Diseases, Frederiksberg Hospital, Frederiksberg; Department of Radiology, Herlev and Gentofte Hospital, Herlev; Center for Rheumatology and Spine Diseases, and Gentofte Hospital, Hellerup, Denmark; Department of Diagnostic Imaging, Sheba Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. The investigator-initiated study was supported by AbbVie, which manufactures adalimumab. S.K. received grants from The Danish Rheumatism Association and Rigshospitalet. S.J.P. has received speaker fees from MSD, Pfizer, AbbVie, Novartis, and UCB; has been an advisory board member for AbbVie, and received research support from AbbVie and MSD. M.Ø. has received research support and/or consultancy/speaker fees from AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Centocor, GSK, Hospira, Janssen, Merck, Mundipharma, Novartis, Novo, Orion, Pfizer, Regeneron, Schering-Plough, Roche, Takeda, UCB, and Wyeth. S. Krabbe, MD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; I. Eshed, MD, Department of Diagnostic Imaging, Sheba Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University; I. Juul Sørensen, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; B. Jensen, MD, Center for Rheumatology and Spine Diseases, Frederiksberg Hospital; J.M. Møller, MSc, Department of Radiology, Gentofte Hospital; L. Balding, MD, Department of Radiology, Gentofte Hospital; O.R. Madsen, MD, PhD, Center for Rheumatology and Spine Diseases, Herlev and Gentofte Hospital; S.J. Pedersen, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; M. Østergaard, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen. Dr. Pedersen and Dr. Østergaard are co-senior authors. Address correspondence to Dr. S. Krabbe, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Valdemar Hansens Vej 17, DK-2600 Glostrup, Denmark. E-mail: simonkrabbe@gmail.com. Accepted for publication March 1, 2019.
Ole Rintek Madsen
From the Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen; Center for Rheumatology and Spine Diseases, Frederiksberg Hospital, Frederiksberg; Department of Radiology, Herlev and Gentofte Hospital, Herlev; Center for Rheumatology and Spine Diseases, and Gentofte Hospital, Hellerup, Denmark; Department of Diagnostic Imaging, Sheba Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. The investigator-initiated study was supported by AbbVie, which manufactures adalimumab. S.K. received grants from The Danish Rheumatism Association and Rigshospitalet. S.J.P. has received speaker fees from MSD, Pfizer, AbbVie, Novartis, and UCB; has been an advisory board member for AbbVie, and received research support from AbbVie and MSD. M.Ø. has received research support and/or consultancy/speaker fees from AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Centocor, GSK, Hospira, Janssen, Merck, Mundipharma, Novartis, Novo, Orion, Pfizer, Regeneron, Schering-Plough, Roche, Takeda, UCB, and Wyeth. S. Krabbe, MD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; I. Eshed, MD, Department of Diagnostic Imaging, Sheba Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University; I. Juul Sørensen, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; B. Jensen, MD, Center for Rheumatology and Spine Diseases, Frederiksberg Hospital; J.M. Møller, MSc, Department of Radiology, Gentofte Hospital; L. Balding, MD, Department of Radiology, Gentofte Hospital; O.R. Madsen, MD, PhD, Center for Rheumatology and Spine Diseases, Herlev and Gentofte Hospital; S.J. Pedersen, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; M. Østergaard, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen. Dr. Pedersen and Dr. Østergaard are co-senior authors. Address correspondence to Dr. S. Krabbe, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Valdemar Hansens Vej 17, DK-2600 Glostrup, Denmark. E-mail: simonkrabbe@gmail.com. Accepted for publication March 1, 2019.
Susanne Juhl Pedersen
From the Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen; Center for Rheumatology and Spine Diseases, Frederiksberg Hospital, Frederiksberg; Department of Radiology, Herlev and Gentofte Hospital, Herlev; Center for Rheumatology and Spine Diseases, and Gentofte Hospital, Hellerup, Denmark; Department of Diagnostic Imaging, Sheba Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. The investigator-initiated study was supported by AbbVie, which manufactures adalimumab. S.K. received grants from The Danish Rheumatism Association and Rigshospitalet. S.J.P. has received speaker fees from MSD, Pfizer, AbbVie, Novartis, and UCB; has been an advisory board member for AbbVie, and received research support from AbbVie and MSD. M.Ø. has received research support and/or consultancy/speaker fees from AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Centocor, GSK, Hospira, Janssen, Merck, Mundipharma, Novartis, Novo, Orion, Pfizer, Regeneron, Schering-Plough, Roche, Takeda, UCB, and Wyeth. S. Krabbe, MD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; I. Eshed, MD, Department of Diagnostic Imaging, Sheba Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University; I. Juul Sørensen, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; B. Jensen, MD, Center for Rheumatology and Spine Diseases, Frederiksberg Hospital; J.M. Møller, MSc, Department of Radiology, Gentofte Hospital; L. Balding, MD, Department of Radiology, Gentofte Hospital; O.R. Madsen, MD, PhD, Center for Rheumatology and Spine Diseases, Herlev and Gentofte Hospital; S.J. Pedersen, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; M. Østergaard, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen. Dr. Pedersen and Dr. Østergaard are co-senior authors. Address correspondence to Dr. S. Krabbe, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Valdemar Hansens Vej 17, DK-2600 Glostrup, Denmark. E-mail: simonkrabbe@gmail.com. Accepted for publication March 1, 2019.
Mikkel Østergaard
From the Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen; Center for Rheumatology and Spine Diseases, Frederiksberg Hospital, Frederiksberg; Department of Radiology, Herlev and Gentofte Hospital, Herlev; Center for Rheumatology and Spine Diseases, and Gentofte Hospital, Hellerup, Denmark; Department of Diagnostic Imaging, Sheba Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. The investigator-initiated study was supported by AbbVie, which manufactures adalimumab. S.K. received grants from The Danish Rheumatism Association and Rigshospitalet. S.J.P. has received speaker fees from MSD, Pfizer, AbbVie, Novartis, and UCB; has been an advisory board member for AbbVie, and received research support from AbbVie and MSD. M.Ø. has received research support and/or consultancy/speaker fees from AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Centocor, GSK, Hospira, Janssen, Merck, Mundipharma, Novartis, Novo, Orion, Pfizer, Regeneron, Schering-Plough, Roche, Takeda, UCB, and Wyeth. S. Krabbe, MD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; I. Eshed, MD, Department of Diagnostic Imaging, Sheba Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University; I. Juul Sørensen, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; B. Jensen, MD, Center for Rheumatology and Spine Diseases, Frederiksberg Hospital; J.M. Møller, MSc, Department of Radiology, Gentofte Hospital; L. Balding, MD, Department of Radiology, Gentofte Hospital; O.R. Madsen, MD, PhD, Center for Rheumatology and Spine Diseases, Herlev and Gentofte Hospital; S.J. Pedersen, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; M. Østergaard, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen. Dr. Pedersen and Dr. Østergaard are co-senior authors. Address correspondence to Dr. S. Krabbe, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Valdemar Hansens Vej 17, DK-2600 Glostrup, Denmark. E-mail: simonkrabbe@gmail.com. Accepted for publication March 1, 2019.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Whole-body Magnetic Resonance Imaging Inflammation in Peripheral Joints and Entheses in Axial Spondyloarthritis: Distribution and Changes during Adalimumab Treatment
Simon Krabbe, Iris Eshed, Inge Juul Sørensen, Bente Jensen, Jakob M. Møller, Lone Balding, Ole Rintek Madsen, Susanne Juhl Pedersen, Mikkel Østergaard
The Journal of Rheumatology Apr 2019, jrheum.181159; DOI: 10.3899/jrheum.181159
Whole-body Magnetic Resonance Imaging Inflammation in Peripheral Joints and Entheses in Axial Spondyloarthritis: Distribution and Changes during Adalimumab Treatment
Simon Krabbe, Iris Eshed, Inge Juul Sørensen, Bente Jensen, Jakob M. Møller, Lone Balding, Ole Rintek Madsen, Susanne Juhl Pedersen, Mikkel Østergaard
The Journal of Rheumatology Apr 2019, jrheum.181159; DOI: 10.3899/jrheum.181159